Malecare and the University of Minnesota are well on the way to making the Restore study, the largest and most comprehensive survey of gay and bisexual men with prostate cancer ever conducted. The Restore study is funded by the National Cancer Institute at NIH and is now recruiting men to complete their survey. You can [...]
For men with metastatic prostate cancer, understanding ones prostate specific antigen (PSA) kinetics is important. Despite the issues we hear surrounding the PSA, it is still the best measure you have in aiding you in the assessing your possible outcome prognosis. PSA kinetics also are a potential surrogate marker for clinical trial results. In most [...]
Teva Pharmaceutical Industries has received approval and launched, in the United States, a generic version of the Avodart (dutasteride) capsules at the 0.5 mg dose. Avodart, 5-alpha reductase inhibitor, is FDA approved for the treatment of men with benign prostate hyperplasia (an enlarged prostate gland), however, although not approved; men often use it as a [...]
There are many trials and tribulations facing new drug approvals for men with prostate cancer. This is particularly true for men the drugs that are designed to fight metastatic castration-resistant prostate cancer (mCRPC) because of the many new treatments, all with life extending ability, that we now have available to use. The good news is [...]
I stumbled upon a fascinating piece of research from Iceland that looked at the role of Circadian Disruption in Prostate Cancer Development. Knowing my own very poor sleeping patterns and having heard many other men with advanced prostate cancer complaining about very similar experiences it peaked my interest. The researchers pointed out that there have [...]